State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Intuitive Surgical, Inc. — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Intuitive Surgical, Inc. trades at $402.08 (market cap $141.75B). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| FLRN | ISRG | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $30.86 | $592.85 |
52-Week Low | $30.65 | $332.02 |
Market Cap | — | $141.75B |
Enterprise Value | — | $136.53B |
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though the RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Current financial ratios including P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunity exists in the steady dividend yield, but risks include potential interest rate sensitivity as highlighted in recent financial commentary. Investors should seek updated financial statements for comprehensive analysis given the missing valuation metrics.
Intuitive Surgical (ISRG) trades at $403.95, up 2.69% on the day, reflecting strong momentum. The stock exhibits bullish technical signals with support at $398 and resistance at $403. Fundamentally, revenue grew to $10.06B in 2025 with a net income margin of 28.45%, though valuation ratios like a P/E of 46.01 suggest premium pricing. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.80 exceeding expectations. News highlights analyst upgrades and robust adoption of the da Vinci 5 system.
Outlook remains positive driven by innovation and market expansion, but high valuation and competitive pressures pose risks. The consensus price target of $518.10 implies significant upside, supported by 68% buy ratings from analysts. Key risks include reliance on U.S. procedure growth and rising competition from Medtronic and Johnson & Johnson. Long-term growth prospects appear solid if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →